NO20065137L - Vannloselig prolegemiddel - Google Patents

Vannloselig prolegemiddel

Info

Publication number
NO20065137L
NO20065137L NO20065137A NO20065137A NO20065137L NO 20065137 L NO20065137 L NO 20065137L NO 20065137 A NO20065137 A NO 20065137A NO 20065137 A NO20065137 A NO 20065137A NO 20065137 L NO20065137 L NO 20065137L
Authority
NO
Norway
Prior art keywords
water soluble
soluble prodrug
prodrug
represented
water
Prior art date
Application number
NO20065137A
Other languages
English (en)
Norwegian (no)
Inventor
Jun Ohwada
Sawako Ozawa
Isao Umeda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20065137L publication Critical patent/NO20065137L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO20065137A 2004-04-09 2006-11-08 Vannloselig prolegemiddel NO20065137L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004115713 2004-04-09
PCT/JP2005/006957 WO2005097803A1 (ja) 2004-04-09 2005-04-08 新規水溶性プロドラッグ

Publications (1)

Publication Number Publication Date
NO20065137L true NO20065137L (no) 2006-12-21

Family

ID=35124997

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065137A NO20065137L (no) 2004-04-09 2006-11-08 Vannloselig prolegemiddel

Country Status (18)

Country Link
US (1) US7910593B2 (xx)
EP (1) EP1757609B1 (xx)
JP (1) JP4823894B2 (xx)
KR (1) KR20070011457A (xx)
CN (1) CN1964979B (xx)
AU (1) AU2005230994A1 (xx)
BR (1) BRPI0509732A (xx)
CA (1) CA2563502A1 (xx)
HK (1) HK1100083A1 (xx)
IL (1) IL178465A0 (xx)
MX (1) MXPA06011679A (xx)
MY (1) MY145850A (xx)
NO (1) NO20065137L (xx)
NZ (1) NZ550665A (xx)
RU (1) RU2413731C2 (xx)
TW (1) TWI351284B (xx)
UA (1) UA88008C2 (xx)
WO (1) WO2005097803A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532882A (en) * 2001-11-23 2007-07-27 Chugai Pharmaceutical Co Ltd Method for identification of tumor targeting enzymes
EP1599484A2 (en) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
CN1964979B (zh) 2004-04-09 2011-07-27 中外制药株式会社 新颖的水溶性前药
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
WO2008029200A1 (en) * 2006-09-03 2008-03-13 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
CA2782398C (en) * 2009-12-09 2017-09-26 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
WO2014067960A2 (en) * 2012-10-30 2014-05-08 Nerviano Medical Sciences S.R.L. Functionalized 9-bromo-camptothecin derivatives
RU2748260C2 (ru) 2016-04-04 2021-05-21 Кемосентрикс, Инк. РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ
CN111295368A (zh) 2017-09-22 2020-06-16 大日本住友制药株式会社 化学活化型水溶性前药
EP4176904A1 (en) 2019-03-29 2023-05-10 MedImmune Limited Compounds and conjugates thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0220601B1 (en) 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0271836A (ja) 1988-09-05 1990-03-12 Agency Of Ind Science & Technol 繊維状極小分子集合体の製法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
HU213136B (en) 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
NZ242117A (en) 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JP2967184B2 (ja) 1996-03-07 1999-10-25 工業技術院長 オリゴペプチド鎖のｃ端を両端にもつ双頭型脂質の製造方法
EP0897924B1 (en) 1996-04-26 2001-10-31 Daiichi Pharmaceutical Co., Ltd. Process for the preparation of tetrahydro-indolizines
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
EP1017675B1 (en) 1997-02-14 2006-06-14 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6265540B1 (en) * 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
ES2235336T3 (es) 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
DE69840216D1 (de) * 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
JP4102466B2 (ja) 1997-11-14 2008-06-18 株式会社アミノアップ化学 抗癌剤の副作用軽減剤
US6130039A (en) * 1997-12-12 2000-10-10 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human lysyl hydroxylase-like protein
TWI244924B (en) * 1998-01-23 2005-12-11 Newbiotics Inc Enzyme catalyzed therapeutic agents
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
EA008060B1 (ru) 1998-09-04 2007-02-27 Милленниум Фармасьютикалз, Инк. Антагонисты хемокинного рецептора и способы их применения
BR0008524A (pt) * 1999-02-27 2001-12-18 Boehringer Ingelheim Pharma Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
WO2000063418A1 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Protein transport assays
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DE60034954D1 (de) 1999-09-14 2007-07-05 Xenoport Inc Substrate und screeningverfahren für transportproteine
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
KR100717916B1 (ko) 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
AU2001268653A1 (en) 2000-06-28 2002-01-08 Supergen, Inc. Combination hiv therapy including camptothecin
EP1358612A2 (en) 2000-07-28 2003-11-05 LION Bioscience AG Regional intestinal permeability model
JP4244141B2 (ja) 2000-11-07 2009-03-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 血液腫瘍および血液癌を処置する方法
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6803186B2 (en) 2001-03-02 2004-10-12 The Iams Company Compositions and methods for increasing amino acid absorption in mammals
EP1406493A4 (en) 2001-06-11 2006-06-14 Xenoport Inc ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
NZ532882A (en) 2001-11-23 2007-07-27 Chugai Pharmaceutical Co Ltd Method for identification of tumor targeting enzymes
CN100338066C (zh) 2001-11-30 2007-09-19 中外制药株式会社 六环化合物
CN1802152A (zh) 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1599484A2 (en) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
JP2005255643A (ja) 2004-03-15 2005-09-22 Masato Kusunoki 抗腫瘍効果増強方法および抗腫瘍効果増強剤
CN1964979B (zh) 2004-04-09 2011-07-27 中外制药株式会社 新颖的水溶性前药
ATE435214T1 (de) 2004-09-02 2009-07-15 Vertex Pharma Als ionenkanalmodulatoren geeignete chinazoline
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug

Also Published As

Publication number Publication date
UA88008C2 (xx) 2009-09-10
IL178465A0 (en) 2007-02-11
RU2006139644A (ru) 2008-05-20
US20080015157A1 (en) 2008-01-17
CA2563502A1 (en) 2005-10-20
CN1964979B (zh) 2011-07-27
EP1757609A1 (en) 2007-02-28
MY145850A (en) 2012-04-30
TWI351284B (en) 2011-11-01
CN1964979A (zh) 2007-05-16
MXPA06011679A (es) 2007-01-23
KR20070011457A (ko) 2007-01-24
JPWO2005097803A1 (ja) 2008-02-28
HK1100083A1 (en) 2007-09-07
RU2413731C2 (ru) 2011-03-10
AU2005230994A1 (en) 2005-10-20
US7910593B2 (en) 2011-03-22
EP1757609B1 (en) 2013-10-16
NZ550665A (en) 2010-05-28
BRPI0509732A (pt) 2007-09-25
EP1757609A4 (en) 2010-09-01
JP4823894B2 (ja) 2011-11-24
TW200600088A (en) 2006-01-01
WO2005097803A1 (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
NO20065137L (no) Vannloselig prolegemiddel
NO20064077L (no) Kemokinreseptorantagonister
WO2006113552A8 (en) Cyanoarylamines
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
UA80834C2 (en) Method of synthesising ivabradine and the salts thereof for addition to a pharmaceutically acceptable acid
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
EP1854789A4 (en) CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
TW200700397A (en) Novel hsp90 inhibitor
NO20084127L (no) Benzylfenylglukopyranosidderivat
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
MX2009006907A (es) Activador de glucocinasa.
EP1760073A4 (en) SULPHONAMIDE COMPOUND
WO2005094329A8 (en) Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
JO2413B1 (en) Benzoxazine derivatives and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application